Structure and function of an irreversible agonist-β(2) adrenoceptor complex
Daniel M Rosenbaum1, Cheng Zhang, Joseph A Lyons
1Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, USA.
Nature
|January 14, 2011
Summary
Researchers developed a novel covalent agonist for the beta-2 adrenergic receptor (β(2)AR). This stabilized the receptor
Area of Science:
- Structural biology
- Biochemistry
- Molecular pharmacology
Background:
- G-protein-coupled receptors (GPCRs) are crucial cell signaling proteins, but agonist binding mechanisms remain unclear.
- Understanding GPCR activation is key for drug design, yet crystallizing agonist-bound states is challenging due to weak ligand interactions.
- The human beta-2 adrenergic receptor (β(2)AR) is a well-studied GPCR, but its active conformation is difficult to capture structurally.
Purpose of the Study:
- To determine the high-resolution structure of an agonist-bound GPCR.
- To elucidate the molecular basis of GPCR activation and allosteric modulation.
- To enable structure-guided design of novel GPCR-targeting therapeutics.
Main Methods:
- Design and synthesis of a novel covalent agonist for the β(2)AR, tethered via a disulfide bond.
- Formation of a stable covalent β(2)AR-agonist complex capable of G protein activation.
- Crystallization of the covalent agonist-bound β(2)AR-T4L fusion protein in lipid bilayers using the lipidic mesophase method.
- Determination of the complex's structure at 3.5 Å resolution.
Main Results:
- A stable covalent agonist-bound β(2)AR complex was successfully created and crystallized.
- Structural analysis revealed the receptor's active conformation, requiring interactions at both extracellular and intracellular surfaces.
- Molecular dynamics simulations (up to 30 µs) showed the active state's instability without G protein or stabilizing antibody.
Conclusions:
- A covalent agonist strategy overcomes challenges in crystallizing agonist-bound GPCRs.
- The determined structure provides critical insights into the conformational changes required for β(2)AR activation.
- This work advances the understanding of GPCR activation mechanisms and facilitates structure-based drug discovery.
More Related Videos
Related Concept Videos
Drug-Receptor Interaction: Agonist
4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Combined Effects of Drugs: Antagonism
11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K


